SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is surging as investors speculate on a potential buyout following executive severance changes and the highly anticipated upcoming Phase 3 trial data readout. The community is heavily focused on a potential short squeeze, noting record short interest and soaring borrow costs that are fueling significant upward momentum.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is trending due to significant momentum in the memory and storage sector, driven by strong AI-related demand and an ongoing rally among industry peers. The community remains divided, with many traders debating whether the stock is undergoing a structural rerating or experiencing an unsustainable parabolic bubble fueled by retail FOMO and institutional rotation.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor Corp. is trending as investors weigh the strategic potential of its major all-stock acquisition of Synaptics against immediate concerns regarding share dilution and execution risk. The community remains divided between those bracing for further downside due to the complex integration, and those viewing the current price pullback as an attractive entry point to capitalize on long-term growth in edge AI and industrial power infrastructure.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is facing intense volatility and selling pressure as investors grapple with debt concerns, leadership criticism, and the company's recent move into AI infrastructure partnerships. The community remains deeply divided, with some traders viewing the current price as a tactical buying opportunity while others express significant skepticism regarding management's strategic direction and the impact of the ongoing steel price environment.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors react to robust clinical data from its next-generation obesity pipeline, including strong results for retatrutide and Foundayo. The stock is seeing significant institutional attention and bullish sentiment, with market participants actively discussing its competitive dominance in the GLP-1 sector and strategic expansion into broader indications like oncology and neuroscience.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors weigh the potential impact of a long-awaited appellate court decision regarding Medicare bundling against the company's strong revenue growth and expanding commercial presence. The community is actively debating the stock's valuation disconnect and potential consolidation in the nephrology sector, with many long-term shareholders remaining focused on fundamental execution while monitoring institutional activity for signs of a turnaround.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy is experiencing significant price volatility following news of a suspended data center project in Wyoming, which had previously included plans for the deployment of the company's fuel cell technology. While some market participants are expressing concern over valuation and potential project headwinds, others in the community view this pullback as a structural buying opportunity, citing the company's robust backlog and the ongoing surge in data center power demand.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is currently a focal point of intense community speculation, with retail investors attempting to force a short squeeze by piling into shares and encouraging long-term holding to counteract short-selling pressure. The trend is fueled by nostalgia for fast-food culture and a narrative that the company's dividend-paying fundamentals and potential for a corporate turnaround make it an undervalued, meme-worthy target similar to past retail-driven market events.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is experiencing a period of intense volatility and high retail engagement, driven by a mixture of excitement surrounding the company's platform-based business model and ongoing debates over its long-term stock performance. Investors remain polarized, with many aggressively accumulating shares in anticipation of upcoming clinical readouts in the second half of the year, while skeptics point to the stock's historical underperformance and recurring post-earnings price declines as signs of structural weakness.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense community discussion surrounding its production scaling efforts, specifically the goal to increase capacity to one million units per month within the next year. While many investors are bullish on the potential for massive revenue growth and the company's role in AI infrastructure, others remain skeptical due to past timeline shifts and are closely monitoring the upcoming annual meeting for concrete evidence of execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors

Aktis Oncology (NASDAQ:AKTS) outlined its clinical development strategy for AKY-2519, a B7-H3 targeted miniprotein radioconjugate, emphasizing a two-trial approach intended to generate...

Aktis Oncology (AKTS) Expected to Announce Earnings on Friday

Aktis Oncology (NASDAQ:AKTS) will be releasing its Q1 2026 earnings on Friday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-8-akoustis-technologies-inc-stock...

Aktis Oncology (NASDAQ:AKTS) Shares Gap Down - What's Next?

Aktis Oncology (NASDAQ:AKTS) Shares Gap Down - Time to Sell...

Aktis Oncology (NASDAQ:AKTS) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?

Aktis Oncology (NASDAQ:AKTS) Stock Crosses Above Fifty Day Moving Average - Time to Sell...

Wall Street Analysts Predict a 74.73% Upside in Aktis (AKTS): Here's  What You Should Know

The mean of analysts' price targets for Aktis (AKTS) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Aktis Oncology (NASDAQ:AKTS) Shares Down 3.7% - Here's Why

Aktis Oncology (NASDAQ:AKTS) Stock Price Down 3.7% - Time to Sell...

Aktis Oncology (NASDAQ:AKTS) Receives Consensus Rating of "Buy" from Analysts

Shares of Aktis Oncology (NASDAQ:AKTS - Get Free Report) have been given an average rating of "Buy" by the five analysts that are presently covering the stock, MarketBeat Ratings reports. Five...

Q1 EPS Estimates for Aktis Oncology Boosted by HC Wainwright

Aktis Oncology (NASDAQ:AKTS - Free Report) - Investment analysts at HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Aktis Oncology in a research report issued to clients...

HC Wainwright Comments on Aktis Oncology Q1 Earnings

Aktis Oncology (NASDAQ:AKTS - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Aktis Oncology in a research note issued on Tuesday, March 31st. HC...

Aktis Oncology (NASDAQ:AKTS) Given New $33.00 Price Target at HC Wainwright

HC Wainwright boosted their price objective on Aktis Oncology from $30.00 to $33.00 and gave the company a "buy" rating in a report on Tuesday...

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.

Aktis Oncology Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$29.18
Prev Close	$31.15
Open	$31.58
Dividend Yield	N/A
50-Day Moving Average	$20.55
Beta	2.37
Avg. Volume	150,095.60
PE Ratio	N/A

52-Week High	$33.53
52-Week Low	$0.0372
Market Capitalization	$1.72B
EPS (Annual)	-$1.19
Price to Book	3.40
Revenue Per Employee	$82,240.51

Feed

News

Sentiment

Earnings

Fundamentals

Info

AKTSAkoustis Technologies Inc

Latest AKTS News